DSM Pharmaceutical Products appoints new ceo

Alexander Wessels takes a new role

Alexander (‘Xander’) Wessels, previously president and ceo of DSM Food Specialties, has taken responsibility for DSM Pharmaceutical Products, the pharmaceutical ingredients and contract manufacturing division of Royal DSM.

Wessels reports to Stephan Tanda, member of the DSM managing board, and will oversee the implementation of DSM’s global growth strategy within the pharmaceutical products business group. The strategy, announced last September, includes sales from high-growth economies, innovation and sustainability solutions as well as from partnerships.

Wessels has worked in the life sciences, nutrition and pharmaceutical industries for 20 years, including four years at DSM, most recently as Business Group President of DSM Food Specialties, improving the division’s performance.

The DSM Pharmaceutical Products business group, headquartered in Parsippany, NJ, US, offers manufacturing services, r&d/formulation and technologies for biologics, active pharmaceutical ingredients and intermediates, as well as finished dosage manufacturing. The business group works closely with all DSM pharma interests including DSM Anti-Infectives.

Prior to joining DSM, Wessels held various management and executive positions in the food, beverage and nutrition industries at Unilever, Quest International (Unilever), ICI, and Campina.

You may also like

Ingredients

dsm-firmenich showcases excipient and sustainability solutions at CPHI Milan

The company will present its range of solutions designed to boost patient compliance, while also exhibiting its pharma-grade CBD ingredient
Ingredients

The roadmap to success in the cannabinoid drug development journey

The key to success in the development and registration of cannabinoid-based medicines hinges on choosing a GMP-certified high-purity active ingredient that is of natural origin and supported by regulatory documentation. Drug developers looking to take product development further still should also consider patient-centricity during formulation and strategies to boost the efficacy of cannabinoids by optimising their bioavailability profile
Manufacturing

dsm-firmenich initiates patent infringement action

dsm-firmenich asserts that Shengda’s production of a key biotin intermediate at its Anhui site is an unlawful use of patented technology
Ingredients

What role can CBD play to support mental health?

Talking to Dr Kevin Robinson (KSR), DSM’s Clinical Project Scientist, Mariana Coelho (MC), shares the latest scientific findings behind CBD and how it could help to support mental health and well-being on a global scale, especially as the demand for viable treatments continues to grow
Ingredients

CBD: the new frontier in medical science

Early stage drug development plays an important role in expanding treatment options that will support the health of patients globally. To create bespoke drug products, it is important to explore and understand the benefits of new actives emerging on the market, such as cannabidiol (CBD), explains Kelsey Achenbach, Senior Director, Pharma and Medical Nutrition at DSM
Ingredients

Humanetics acquires all legal assets of DSM radioprotective API

All patents, trademarks, trade secret manufacturing processes of the API for BIO 300 have been sold to US-based Humanetics
Ingredients

DSM at CPhI: the rapidly evolving role of vitamins and lipids in disease management

Royal DSM, a global science-based company active in nutrition, health and sustainable living, invites you to discover the evolving role of vitamins and lipids in pharmaceutical applications at CPhI Worldwide 2018
Subscribe now